President Donald Trump has announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of certain fertility drugs used for in-vitro fertilization, or IVF.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
